A-Spasm5 mg

A-Spasm is an anticholinergic (antimuscarinic) antispasmodic agent used for the following indications:

Established / Guideline-Supported Uses

• Symptomatic relief of gastrointestinal (GI) spasm and hypermotility disorders, including pylorospasm and spastic (irritable) colon
• Adjunctive, symptomatic treatment of peptic ulcer disease (duodenal and gastric ulcer) — to reduce gastric acid hypersecretion and relieve associated smooth-muscle spasm and pain, used together with appropriate definitive/eradication therapy (e.g., for H. pylori) when indicated
• Relief of biliary colic and renal/ureteric colic as an adjunct to primary management

Adjunct / Combination-Dependent Uses

• As an adjunct antispasmodic in the management of functional GI motility disorders, generally alongside dietary and other pharmacologic measures

Important: A-Spasm provides symptomatic relief only; it does not treat the underlying cause of peptic ulcer disease (such as H. pylori infection) and should be used alongside, not instead of, definitive causal therapy when one exists.

Each tablet of Oxyphenonium Bromide generally contains 5 mg of Oxyphenonium Bromide as the active ingredient, formulated with standard pharmaceutical excipients. Strength and formulation may vary by manufacturer; refer to the specific product label for exact composition.

A-Spasm is a synthetic quaternary ammonium anticholinergic (antimuscarinic) compound with antispasmodic properties. It acts peripherally on smooth muscle and glandular tissue to reduce gastrointestinal motility and secretions, and is used mainly for the symptomatic relief of GI spasm and hyperacidity-related discomfort. Because it is a quaternary ammonium compound, A-Spasm does not readily cross the blood-brain barrier, so central nervous system effects are minimal compared with tertiary-amine anticholinergics.

A-Spasm belongs to the Anticholinergic (Antimuscarinic) Antispasmodic class of medicines.

Oxyphenonium Bromide is a competitive antagonist at muscarinic acetylcholine receptors located on smooth muscle, cardiac muscle, and exocrine glands. By blocking the action of acetylcholine at these post-ganglionic parasympathetic sites, Oxyphenonium Bromide:

• Relaxes smooth muscle of the gastrointestinal tract, reducing spasm and motility
• Reduces gastric acid secretion and salivary/other exocrine gland secretions
• Produces mild inhibitory effects on the biliary and urinary tracts

As a quaternary ammonium compound, Oxyphenonium Bromide is poorly absorbed orally and does not cross the blood-brain barrier appreciably, limiting central anticholinergic effects relative to tertiary-amine antimuscarinics.

A-Spasm tablets are usually taken orally, about 30 minutes before meals and again at bedtime, with a glass of water. It may be taken with food if stomach upset occurs, but taking A-Spasm before meals generally provides better control of GI hyperacidity/spasm. Do not chew or crush the tablet unless directed. Follow the dose and schedule advised by the prescribing physician.

A-Spasm has the following clinically significant drug interactions:

• Other anticholinergic/antimuscarinic drugs (e.g., tricyclic antidepressants, certain antihistamines, phenothiazines, other antispasmodics): concurrent use with A-Spasm may additively increase anticholinergic effects such as dry mouth, blurred vision, constipation, and urinary retention.
• Oral medications requiring adequate gastric motility for absorption: by slowing gastric emptying and GI motility, A-Spasm may alter the rate or extent of absorption of other orally administered drugs.
• Antacids: may reduce the absorption of A-Spasm if taken simultaneously; separate dosing times where possible.

Common side effects of A-Spasm, related to its anticholinergic activity, include:

• Dry mouth
• Blurred vision
• Constipation
• Urinary hesitancy
• Palpitations/tachycardia
• Decreased sweating
• Headache, dizziness
• Photophobia

Seek medical advice if side effects of A-Spasm are severe or persistent. See Contraindications for conditions in which A-Spasm must not be used, and Precautions and Warnings for conditions requiring caution.

Data on the use of A-Spasm during pregnancy are limited. A-Spasm should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use.

It is not well established whether A-Spasm passes into breast milk. As with other anticholinergics, caution is advised during breastfeeding, and A-Spasm may reduce milk secretion; use only under medical advice.

A-Spasm should be used with caution in:

• Elderly patients, who have increased sensitivity to the anticholinergic effects of A-Spasm (confusion, urinary retention, constipation)
• Patients with cardiac arrhythmias or tachycardia, as A-Spasm can increase heart rate
• Patients with autonomic neuropathy
• Patients with hyperthyroidism
• Patients with benign prostatic hyperplasia not amounting to frank obstruction
• Hot weather/high ambient temperature, since A-Spasm decreases sweating and may predispose to heat prostration or hyperthermia
• Fever, since A-Spasm can further reduce sweating and heat dissipation

See Contraindications for conditions in which A-Spasm must not be used at all.

Overdose with A-Spasm may cause an exaggerated anticholinergic (atropine-like) toxidrome, including severe dry mouth, blurred vision, flushed/hot dry skin, high fever, rapid heart rate, urinary retention, restlessness, confusion, or hallucinations, and in severe cases, respiratory depression.

If overdose of A-Spasm is suspected, seek immediate medical attention or contact emergency services/a poison control center right away. Do not attempt to manage a suspected A-Spasm overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: Use A-Spasm with caution, starting at the lower end of the dosing range, due to increased susceptibility to anticholinergic adverse effects such as confusion, constipation, and urinary retention.

Pediatric patients: Safety and efficacy of A-Spasm in children have not been well established; use only if considered necessary under close medical supervision.

Hepatic/renal impairment: No well-established specific dosing guidance for A-Spasm is available; use cautiously and under medical supervision.

See Contraindications and Precautions and Warnings for populations in whom A-Spasm is contraindicated or requires special caution.

The duration of treatment with A-Spasm should be determined by the prescribing physician based on symptom response, and A-Spasm is generally intended for short-term, symptomatic relief rather than long-term standalone therapy. When used as an adjunct in peptic ulcer disease, A-Spasm should be continued only as long as directed alongside definitive ulcer therapy, and treatment should be re-evaluated if symptoms persist beyond a few weeks.

Anticholinergics (Antimuscarinics) / Antispasmodics

Oxyphenonium Bromide works by competitively blocking muscarinic acetylcholine receptors on gastrointestinal and other smooth muscle, thereby reducing spasm, motility, and glandular (including gastric acid) secretion.

The safety and efficacy of A-Spasm in pediatric patients have not been well established. If use of A-Spasm is considered necessary in a child, it should be undertaken only under close medical supervision, with careful attention to the anticholinergic contraindications and precautions described above.